Recent 8-K filings for PFSA
Highest-materiality recent filing
NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.
- Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
- Issued $10M principal PIPE convertible note to Ascent Partners at 10% OID, 18-month maturity.
-
Profusa granted Nasdaq exception to continue listing; transfer to Capital Market by July 6, 2026
Nasdaq Hearings Panel granted exception to continue listing; must comply with Bid Price Rule and Equity Rule by July 6, 2026.
-
Profusa faces Nasdaq delisting for MVPHS failure; amends debt and warrant terms
Received Nasdaq notice of non-compliance with $15M MVPHS Rule; deadline missed April 27, 2026; response due May 5.
-
Profusa acquires PanOmics platform assets for $30M in convertible preferred stock
Purchase price $30M via Series A Convertible Preferred Stock, convertible to common after 1 year.
-
Profusa Issues $1.11M Convertible Note and Warrant to Ascent Partners Fund LLC
Issued $1,111,111.11 principal Senior Secured Convertible Promissory Note to Ascent Partners Fund LLC for $1,000,000 purchase price, maturing April 20, 2027, with 12% annual interest.
-
Profusa signs LOI to buy PanOmics assets for $30M equity; issues $555k convertible note
Non-binding LOI to acquire Bio Insights' PanOmics assay for $30M in stock (460k common + 59.54M conversion shares) plus 3% annual net revenue royalty.
-
Profusa receives Nasdaq delisting notice; terminates Bitcoin treasury strategy, liquidates holdings
Nasdaq Global Market delisting notice for failure to meet $50M MVLS and $1.00 bid price; deadline March 10, 2026 missed.
-
Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI
Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
-
Profusa shareholders approve reverse stock split authorization up to 1-for-200
Proposal to authorize Board to effect reverse splits at ratios 1-for-30 to 1-for-200 before Jan 27, 2028 passed with 30.8M For, 6.0M Against.
-
Profusa enters Amendment No. 3 to SPA; third tranche up to $5.56M principal, floor price $0.35
Third tranche: up to $5,555,556 principal for $5M purchase price; requires zero balance on prior tranches, Nasdaq listing, and stockholder approval.
-
SPA Amendment lowers Floor Price to $0.111/share for up to 13.65M shares during Modification Period ending upon reverse stock split (expected Jan 2026).
-
Profusa cuts net debt to $14M, gives 2026-2030 revenue targets
Net debt reduced from $48M to $16M in Q3 2025 and to $14M as of Oct 31, 2025.
-
Profusa receives Nasdaq deficiency notice for MVPHS below $15M; 180-day cure period until April 2026
Nasdaq notified Profusa on Oct 27, 2025 that MVPHS was below $15M for 30 consecutive business days from Sep 12 to Oct 24, 2025.
-
Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026
EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
-
Profusa receives Nasdaq MVLS and bid price deficiency notices; 180-day cure period
Nasdaq notified Profusa on Sep 11, 2025, that MVLS was below $50M threshold from Jul 29 to Sep 10.
-
Restructured SPA into four tranches: $10M (closed July 11), $2.22M, $5.56M, $4.44M; aggregate $22.2M principal.
-
Profusa appoints Peter O'Rourke as lead independent director, Fred Knechtel as CFO
Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, joins board as lead independent director.
-
Profusa posts H1 net loss $5.1M; cash at $44K; going concern doubt persists
Net loss $2.3M for Q2 2025, $5.1M for H1 2025; no revenue; R&D $0.8M, G&A $1.6M.
-
Profusa strategy update: $100M ELOC secured, EU launch Q1 2026, FDA submission mid-2026
Became public on Nasdaq July 14, 2025; strategy focused on five pillars including revenue growth and AI infrastructure.
-
Profusa secures up to $100M equity line from Ascent Partners; proceeds to buy Bitcoin
Securities Purchase Agreement with Ascent Partners Fund LLC for up to $100M in common stock purchases.
-
NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.
Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
-
NorthView extends business combination deadline to August 22, 2025
Stockholders approved extension of deadline for initial business combination from June 22, 2025 to August 22, 2025.
-
NorthView stockholders approve merger with Profusa; all proposals pass
All eight proposals approved unanimously; 4,979,599 shares voted (93.1% quorum).
-
NorthView enters non-redemption agreement to backstop trust account for Profusa merger
I-Bankers and Dawson James agree not to redeem shares, ensuring trust balance stays above $1.25M threshold.
-
Stockholders approved four proposals, including extending the deadline to June 22, 2025, and removing net tangible asset limitation.
-
Special meeting adjourned to 11:00 a.m. ET on March 21, 2025, to allow holders who redeemed shares to reverse redemptions.
-
NorthView amends Profusa merger terms and secures up to $20M convertible note financing
Amendment No. 4 lowers earnout revenue target for Milestone IV from $99.7M in FY2025 to $11.864M in FY2026.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material